Hanall Biopharma Cash Flow Quality Index
Hanall Biopharma cash flow quality index. Hanall Biopharma (009420) has a Cash Flow Quality Index of 24.56x as of September 2025. Operating cash flow of ₩7.34 Billion exceeds net income of ₩298.96 Million, indicating high earnings quality where cash backs reported profits. Explore Hanall Biopharma (009420) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Hanall Biopharma (2016–2023)
Cash flow quality index of Hanall Biopharma from 2016 to 2023. Historical Cash Flow Quality Index for Hanall Biopharma across 8 annual periods. Values consistently above 1.0x indicate high-quality earnings. See 009420 equity financing ratio to measure how much of total assets are equity-financed.
Hanall Biopharma Cash Flow Quality Index by Year (2016–2023)
Hanall Biopharma cash flow quality index by year from 2016 to 2023. Year-by-year earnings quality comparison for Hanall Biopharma. For the full cash flow conversion analysis, see 009420 cash flow metrics.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2023 | 8.45x | ₩29.64 Billion | ₩3.51 Billion | ▼ -33.3% |
| 2022 | 12.68x | ₩25.20 Billion | ₩1.99 Billion | ▲ +14992.1% |
| 2021 | 0.08x | ₩839.87 Million | ₩10.00 Billion | ▲ +97.7% |
| 2020 | 0.04x | ₩929.29 Million | ₩21.87 Billion | ▼ -96.0% |
| 2019 | 1.07x | ₩20.49 Billion | ₩19.17 Billion | ▲ +217.8% |
| 2018 | -0.91x | ₩-2.99 Billion | ₩3.30 Billion | ▼ -112.5% |
| 2017 | 7.25x | ₩42.14 Billion | ₩5.81 Billion | ▲ +271.8% |
| 2016 | 1.95x | ₩3.95 Billion | ₩2.03 Billion | — |